Premium
Pralatrexate for refractory mycosis fungoides in two Japanese patients
Author(s) -
Teraishi Mika,
Oguro Tokuko,
Kusume Ema,
Kobashi Haruka,
Sano Hozumi,
Fujioka Ai,
Yamamoto Mayuko,
Nakajima Hideki,
Sano Shigetoshi
Publication year - 2021
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.15761
Subject(s) - mycosis fungoides , refractory (planetary science) , medicine , peripheral t cell lymphoma , dermatology , oncology , lymphoma , t cell , immunology , immune system , biology , astrobiology
Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced‐stage cutaneous T‐cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein describe two Japanese patients with heavily‐pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate.